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OBSERVATIONS
Diabetes-Related
Autoantibodies in
ChildrenWith Acute
Lymphoblastic
Leukemia
Acute lymphoblastic leukemia (ALL)is the most common subtype of leu-kemia in children. Although ALL and
type 1 diabetes appear to be biologically
unrelated, there are common threads in
both epidemiology and etiology. Rising
incidence rates of both ALL (1) and type 1
diabetes (2) observed over recent decades
in many Western countries seem to sup-
port common etiological factors (3).
In the current study, we report on
diabetes-related autoantibodies (Abs) in
a group of patients with ALL. Thirty-four
consecutive children (19 males and 15 fe-
males, mean age 6.2 6 4.6 years) were re-
ferred to our institution in 2004 for newly
diagnosedALL. Patientswere tested for Abs
to islet and thyroid antigens. After the ini-
tial investigation and treatment, 31/34
(91%) patients (3 died in the mean time)
were followedup for 6 years to evaluate
the evolution of the autoimmune markers
and progression toward type 1 diabetes.
Glutamic acid decarboxylase (GAD)
Abs by direct radioligand assay (Centak,
Medipan, Germany), insulin Abs (IAA) by
a semiquantitative radioimmunoassay (AIA
2100; DIAsource, Nivelles, Belgium), IA2
Abs by a direct radioligand assay (Centak,
Medipan, Germany), and thyroperoxidase
Abs (TPOAbs) by an ultrasensitive chemi-
luminescent enzyme immunoassays by
Advia Centaur (Bayer HealthCare LLCDivi-
sion, Tarrytown, NY) were measured twice
at diagnosis and after 6 years. Our labora-
tory participated in the latest 2010 Diabe-
tes Antibody Standardization Program.
Seven children (20.5%) showed at
least one diabetes-related Ab; two chil-
dren (5.9%) were found positive for all
three Abs (GAD, IAA, and IA2) with one of
the two also showing TPOAbs positivity;
isolated IAA positivity was found in ﬁve
(14.7%) children. Autoantibodies retested
in the 31 surviving children 6 years later
were found to be negative in all patients.
Also, none of the children who were Abs
negative at ALL diagnosis became Abs pos-
itive at follow-up. No patient manifested
hyperglycemia during ALL therapy, and
none developed type 1 diabetes and/or
autoimmune thyroiditis during follow-up.
Finally, in Abs-positive ALL patients
HLA typewas not typical of type 1 diabetes,
and indeed, only one patient showed amod-
erate risk HLA genotype for type 1 diabetes.
Our data suggest that the activation of
the immune system against self-antigens
in childhood ALL is nonspeciﬁc and self-
limiting, even though chemotherapy may
contribute to suppress autoimmunity dur-
ing follow-up. The dysregulation of the im-
mune response in ALL is probably related to
the profound functional derangement of the
immune response during malignancy. The
relatively low Ab titer in ALL children sup-
ports the hypothesis that the autoimmune
process in ALL is not an aggressive one.
Genome-wide association studies
identiﬁed an ALL susceptibility locus
near the IKZF1 gene (4). Recently, one of
these single nucleotide polymorphisms
(rs10272724) conferring susceptibility to
ALL was found to be protective against
type 1 diabetes in a large population of
patients of European ancestry (5). Very
likely genetic susceptibility to type 1 diabe-
tes and ALL is regulated by distinct genes.
In conclusion, the autoimmune humoral
response may start in ALL children as a
consequence of the disease, but it should
be considered as an epiphenomenon re-
lated to the general immune dysregulation.
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